Business Context and Reporting Period
This Form 8-K is a current report filed by Angion Biomedica Corp. (not Elicio Therapeutics, Inc.) on June 29, 2022. The registrant is an emerging growth company incorporated in Delaware with its principal executive offices in Uniondale, New York. The report addresses Item 2.02 regarding Results of Operations and Financial Condition.
Key Financial Metrics
- Liquidity: The company expects cash and cash equivalents as of June 30, 2022, to total more than $60 million.
- Revenue, Profit, Margins, Debt: The filing text does not provide specific values for revenue, net income, operating margins, or debt levels for this period.
- Cash Flow: Specific cash flow figures are not disclosed in this report; only the projected cash balance is stated.
Material Changes
The filing does not provide comparative data against prior periods to quantify material changes in financial performance. The primary disclosure is a forward-looking statement regarding the company's liquidity position as of the end of the second quarter.
Guidance, Outlook, and Management Commentary
Management, represented by President and CEO Jay R. Venkatesan, M.D., announced an expectation that the company will report cash and cash equivalents exceeding $60 million when it releases its second-quarter earnings in August 2022. No other risks, contingencies, or unusual items are detailed in this specific filing.
Investor Verification Checklist
- Verify the actual cash and cash equivalents reported in the upcoming Q2 2022 earnings release scheduled for August 2022.
- Confirm the company's burn rate and runway based on the $60 million liquidity figure.
- Review the full Q2 2022 financial statements for revenue, profit, and debt metrics not included in this 8-K.